190 related articles for article (PubMed ID: 31747911)
21. DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study.
Kim S; Vendrely V; Saint A; André T; Vaflard P; Samalin E; Pernot S; Bouché O; Zubir M; Desrame J; de la Fouchardière C; Smith D; Ghiringhelli F; Vienot A; Jacquin M; Klajer E; Nguyen T; François É; Taieb J; Le Malicot K; Vernerey D; Meurisse A; Borg C
Exp Hematol Oncol; 2023 Jul; 12(1):63. PubMed ID: 37480095
[TBL] [Abstract][Full Text] [Related]
22. Clinical outcomes of chemotherapy-based therapies for previously treated advanced colorectal cancer: a systematic literature review and meta-analysis.
Amonkar MM; Abderhalden LA; Frederickson AM; Aksomaityte A; Lang BM; Leconte P; Zhang I
Int J Colorectal Dis; 2023 Jan; 38(1):10. PubMed ID: 36630020
[TBL] [Abstract][Full Text] [Related]
23. Which is better for gastric cancer patients, perioperative or adjuvant chemotherapy: a meta-analysis.
Zhao JH; Gao P; Song YX; Sun JX; Chen XW; Ma B; Yang YC; Wang ZN
BMC Cancer; 2016 Aug; 16():631. PubMed ID: 27519527
[TBL] [Abstract][Full Text] [Related]
24. Gemcitabine-based chemotherapy as a viable option for treatment of advanced breast cancer patients: a meta-analysis and literature review.
Xie Z; Zhang Y; Jin C; Fu D
Oncotarget; 2018 Jan; 9(6):7148-7161. PubMed ID: 29467957
[TBL] [Abstract][Full Text] [Related]
25. Advanced gastric cancer: Current treatment landscape and future perspectives.
Digklia A; Wagner AD
World J Gastroenterol; 2016 Feb; 22(8):2403-14. PubMed ID: 26937129
[TBL] [Abstract][Full Text] [Related]
26. Second-line treatment of metastatic gastric cancer: Current options and future directions.
Kanagavel D; Fedyanin M; Tryakin A; Tjulandin S
World J Gastroenterol; 2015 Nov; 21(41):11621-35. PubMed ID: 26556991
[TBL] [Abstract][Full Text] [Related]
27. Multimodality treatment for localized gastric cancer: state of the art and new insights.
Petrillo A; Smyth EC
Curr Opin Oncol; 2020 Jul; 32(4):347-355. PubMed ID: 32541324
[TBL] [Abstract][Full Text] [Related]
28. Oxaliplatin-Based Regimen is Superior to Cisplatin-Based Regimen in Tumour Remission as First-line Chemotherapy for Advanced Gastric Cancer: A Meta-Analysis.
Zhang F; Zhang Y; Jia Z; Wu H; Gu K
J Cancer; 2019; 10(8):1923-1929. PubMed ID: 31205551
[No Abstract] [Full Text] [Related]
29. Immunotherapy and targeted therapy as first-line treatment for advanced gastric cancer.
Wang G; Huang Y; Zhou L; Yang H; Lin H; Zhou S; Tan Z; Qian J
Crit Rev Oncol Hematol; 2024 Jun; 198():104197. PubMed ID: 37951282
[TBL] [Abstract][Full Text] [Related]
30. Importance of Progression-free Survival in Second-line Chemotherapy in Patients With Advanced or Recurrent Gastric Cancer.
Sano A; Sohda M; Hosoi N; Tateno K; Watanabe T; Uchida S; Nakazawa N; Osone K; Okada T; Shiraishi T; Sakai M; Ogawa H; Shirabe K; Saeki H
Anticancer Res; 2023 Nov; 43(11):5205-5213. PubMed ID: 37909978
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Role of the Circulating Tumor Cells Detected by Cytological Methods in Gastric Cancer: A Meta-Analysis.
Zou K; Yang S; Zheng L; Wang S; Xiong B
Biomed Res Int; 2016; 2016():2765464. PubMed ID: 27843939
[No Abstract] [Full Text] [Related]
32. Efficacy of Chemoimmunotherapy
Xie J; Chen L; Liu Q; Li XT; Lei XY
Curr Med Chem; 2024; 31(18):2649-2660. PubMed ID: 38265394
[TBL] [Abstract][Full Text] [Related]
33. Free intraperitoneal tumor cells and outcome in gastric cancer patients: a systematic review and meta-analysis.
Pecqueux M; Fritzmann J; Adamu M; Thorlund K; Kahlert C; Reißfelder C; Weitz J; Rahbari NN
Oncotarget; 2015 Nov; 6(34):35564-78. PubMed ID: 26384352
[TBL] [Abstract][Full Text] [Related]
34. Postoperative therapy for local-advanced gastric cancer: A systematic review and meta-analysis.
Wang Z; Dong L; Shi W; Gao L; Jiang X; Xue S; Chang P
Adv Clin Exp Med; 2023 Dec; ():. PubMed ID: 38085005
[TBL] [Abstract][Full Text] [Related]
35. Association of thymidylate synthase expression and clinical outcomes of gastric cancer patients treated with fluoropyrimidine-based chemotherapy: a meta-analysis.
Gao Y; Cui J; Xi H; Cai A; Shen W; Li J; Zhang K; Wei B; Chen L
Onco Targets Ther; 2016; 9():1339-50. PubMed ID: 27022289
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety comparison of chemotherapies for advanced gastric cancer: A network meta-analysis.
Sun J; Ren Z; Sun X; Hou H; Li K; Ge Q
Oncotarget; 2017 Jun; 8(24):39673-39682. PubMed ID: 28562333
[TBL] [Abstract][Full Text] [Related]
37. Delayed Versus Immediate Start of Chemotherapy in Asymptomatic Patients With Advanced Cancer: A Meta-Analysis.
Augustinus S; Thurairajah G; Besselink MG; van Laarhoven HWM; van Oijen MGH; Mackay TM; Wilmink JW
Oncologist; 2023 Nov; 28(11):961-968. PubMed ID: 37589234
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of targeting VEGFR drugs in treatment for advanced or metastatic gastric cancer: a systemic review and meta-analysis.
Liu D; Ma X; Xiao D; Jia Y; Wang Y
Oncotarget; 2018 Jan; 9(8):8120-8132. PubMed ID: 29487720
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapy and Targeted Therapy Strategies in Patients with Unresectable or Borderline Resectable Metastatic Colorectal Cancer: Evidence for a Lack of Focus on Resection Rates.
Zmuc J; Heil J; Herfarth C; Bechstein WO; Koch C; Trojan J; Schnitzbauer AA
Ann Surg Oncol; 2023 Nov; 30(12):7624-7632. PubMed ID: 37644249
[TBL] [Abstract][Full Text] [Related]
40. Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis.
Bittoni A; Del Prete M; Scartozzi M; Pistelli M; Giampieri R; Faloppi L; Bianconi M; Cascinu S
Springerplus; 2015; 4():743. PubMed ID: 26693102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
